Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/00, \ 30/09/01, \ 11/o3/02, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12 \ \ o1/o1/o3, \ o1$ 

LASE	RBOND LTD	
ABN		
24 05	7 636 692	
We (t	he entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	ORD
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	300,000

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

Principal terms of the 3 +securities (eg, if options, exercise price and expiry date; if partly paid +securities, amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Related to Non-Executive Director Remuneration (non-Cash component), with trading restrictions applicable where no trade can be made unless one of the following conditions is met:

- a) Cessation of their Board position for any reason.
- b) Twenty four months passes from the date of issue.

This trade was approved by shareholders at the 2016 Annual General Meeting.

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes.
<ul> <li>not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or</li> </ul>	
• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
Issue price or consideration	\$40,500 at \$0.135 per share based on closing market price on date of shareholder approval of issue.
Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Non-Executive Director Remuneration (Non-Cash component).
Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
The date the security holder resolution under rule 7.1A was passed	24 <sup>th</sup> October 2016
Number of *securities issued without security holder approval	N/A
	in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Issue price or consideration  Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)  Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i  The date the security holder resolution under rule 7.1A was passed

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	300,000 approved 24 <sup>th</sup>	October 2016
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 – 13,564,848 7.1A – 9,043,232	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	25 <sup>th</sup> October 2016	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	90,432,317	Ord

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the securities in section 2 if applicable)	N/A	
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Rank equally from t with all other securitie	he date of allotment es.
Part	2 - Bonus issue or pro ra	ıta issue	
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations	N/A	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
21	How do teconitive helders	NI/A
31	How do *security holders sell part of their entitlements through a broker and accept for	N/A

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

	the balance?		
32	How do *security holders dispo of their entitlements (except l sale through a broker)?	·	
33	<sup>+</sup> Despatch date	N/A	
	3 - Quotation of securion of securion of securion of securion of securion of you are		
34	Type of securities (tick one)		
(a)	Securities described in Pa	art 1	
(b)	All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
	es that have ticked box 34(a)		
	indicate you are providing the infor		
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over		
37	A copy of any trust deed	for the additional <sup>+</sup> securities	

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) Number of securities for which 38 N/A <sup>+</sup>quotation is sought Class of \*securities for which N/A 39 quotation is sought Do the \*securities rank equally in N/A 40 all respects from the date of allotment with an existing +class of quoted \*securities? If the additional securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Reason for request for quotation N/A 41 now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) +Class Number Number and +class of N/A all 42 +securities quoted on ASX (including the securities in clause 38)

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Date:	
0	(Director/Company secretary)	
Print name:		

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	88,440,710	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	1,691,607	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	300,000	
Number of partly paid ordinary securities that became fully paid in that 12 month period	N/A	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	90,432,317	

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	13,564,848
Step 3: Calculate "C", the amount that has already been used	of placement capacity under rule 7.
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	0
• Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	13,564,848
Note: number must be same as shown in Step 2	
Subtract "C"	0
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	13,564,848
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Appendix 3B Page 12 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	9,043,232	
Subtract "E"  Note: number must be same as shown in Step 3	Nil	
<i>Total</i> ["A" x 0.10] – "E"	9,043,232  Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.